Literature DB >> 26416036

Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors.

R Gasparri1, G C Rezende, N Fazio, P Maisonneuve, D Brambilla, L L Travaini, G Paganelli, F Petrella, D Galetta, L Spaggiari.   

Abstract

AIM: The role of fluorodeoxyglucose positron emission tomography (FDG-PET) as an additional investigation to computer tomography for pulmonary carcinoid tumors remains controversial. The aim of this study was to assess the role of FDG-PET for the diagnosis and staging of pulmonary carcinoid tumors.
METHODS: We performed a retrospective mono-institutional analysis of data from 97 patients with pathologically confirmed pulmonary carcinoid tumor who had been operated on between July 1998 and April 2009 and had had a preoperative FDG-PET scan performed.
RESULTS: Sixty-five (67%) of the 97 tumors were typical (TC) and 32 (33%) atypical (AC) carcinoid tumors. Overall FDG-PET sensitivity was 67% being lower for TC (60%) than for AC (81%) (P=0.04). FDG-PET negative tumors were smaller than FDG-PET positive tumors, with a respective median size of 15 and 17 mm (P=0.02). Median SUVmax for FDG-PET-positive tumors was 4.0 (2.8-5.1) with no difference between TC and AC tumors. Median Ki-67 expression was respectively 4.7% and 3.1% for FDG-PET positive and FDG-PET negative tumors (P=0.05). During a median follow-up of 49 months (interquartile range 30-63 months), 9 patients (4TC, 5AC) developed recurrent disease. Neither SUVmax nor Ki-67 expression resulted associated with disease-free survival.
CONCLUSION: With an overall sensitivity of 67%, FDG-PET has shown to be useful in the preoperative work-up of patients with suspect lung carcinoid tumors. In particular it could have a role in larger tumors. These results warrant a prospective evaluation of FDG-PET in the staging of lung carcinoid tumor.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26416036

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  4 in total

Review 1.  The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

Authors:  Nicola Fazio; Antonio Ungaro; Francesca Spada; Chiara Alessandra Cella; Eleonora Pisa; Massimo Barberis; Chiara Grana; Dario Zerini; Emilio Bertani; Dario Ribero; Luigi Funicelli; Guido Bonomo; Davide Ravizza; Juliana Guarize; Filippo De Marinis; Francesco Petrella; Ester Del Signore; Giuseppe Pelosi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

2.  Marked 18-Fuorine-Fluorodeoxyglucose (FDG) Avidity of an Intrapulmonary Typical Carcinoid Tumor Manifesting as a Bronchocele in an Asymptomatic Middle-Aged Woman.

Authors:  Camila Saadé-Yordán; Edward McBurney-Henriquez; Ricardo González-Santoni; Carmen Gurrea-Rosas; José Montalvo-Fitzpatrick; José A Maldonado-Vargas
Journal:  Am J Case Rep       Date:  2017-12-28

3.  The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis.

Authors:  Yuanyuan Jiang; Guozhu Hou; Wuying Cheng
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

4.  Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from 18F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms.

Authors:  Philippe Thuillier; Virginia Liberini; Osvaldo Rampado; Elena Gallio; Bruno De Santi; Francesco Ceci; Jasna Metovic; Mauro Papotti; Marco Volante; Filippo Molinari; Désirée Deandreis
Journal:  Biomedicines       Date:  2021-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.